Cargando…

Clinical evaluation of [(18)F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer’s disease

PURPOSE: The accumulation of misfolded tau is a common feature of several neurodegenerative disorders, with Alzheimer’s disease (AD) being the most common. Earlier we identified JNJ-64326067, a novel isoquinoline derivative with high affinity and selectivity for tau aggregates from human AD brain. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, Mark E., Janssens, Luc, Moechars, Diederik, Rombouts, Frederik J. R., Timmers, Maarten, Barret, Olivier, Constantinescu, Cristian C., Madonia, Jennifer, Russell, David S., Sandiego, Christine M., Kolb, Hartmuth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680304/ https://www.ncbi.nlm.nih.gov/pubmed/32535652 http://dx.doi.org/10.1007/s00259-020-04880-1

Ejemplares similares

Comparison of New Tau PET-Tracer Candidates With [(18)F]T808 and [(18)F]T807
por: Declercq, Lieven, et al.
Publicado: (2016)

T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN
por: Tamagnan, Gilles, et al.
Publicado: (2018)

Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor
por: Timmers, Maarten, et al.
Publicado: (2016)

Flow optimization study of a batch microfluidics PET tracer synthesizing device
por: Elizarov, Arkadij M., et al.
Publicado: (2010)

The development and validation of tau PET tracers: current status and future directions
por: Okamura, Nobuyuki, et al.
Publicado: (2018)

Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils
por: Zhou, Yang, et al.
Publicado: (2021)

Discriminatory ability of next-generation tau PET tracers for Alzheimer’s disease
por: Yap, Steven Y, et al.
Publicado: (2021)

The Sensitivity of Tau Tracers for the Discrimination of Alzheimer’s Disease Patients and Healthy Controls by PET
por: Mohammadi, Zohreh, et al.
Publicado: (2023)

A promising PET tracer candidate targeting α‐synuclein inclusions
por: Xiang, Jie, et al.
Publicado: (2023)

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
por: Novak, Gerald, et al.
Publicado: (2020)

The 3-O sulfation of heparan sulfate proteoglycans contributes to the cellular internalization of tau aggregates
por: Ferreira, Andreia, et al.
Publicado: (2022)

Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue
por: Lemoine, L., et al.
Publicado: (2020)

Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
por: Jie, Caitlin V. M. L., et al.
Publicado: (2021)

Tau Filaments and the Development of Positron Emission Tomography Tracers
por: Goedert, Michel, et al.
Publicado: (2018)

Sustained release of the candidate antiretroviral peptides T-1249 and JNJ54310516-AFP from a rod insert vaginal ring
por: Murphy, Diarmaid J., et al.
Publicado: (2016)

Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates
por: Herrmann, Frank, et al.
Publicado: (2021)

Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo
por: Wang, Peng, et al.
Publicado: (2017)

Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects
por: Miyamoto, Masaomi, et al.
Publicado: (2023)

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2021)

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study
por: Timmers, Maarten, et al.
Publicado: (2018)

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies
por: Brahmer, Julie R., et al.
Publicado: (2020)

Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo
por: Vasconcelos, Bruno, et al.
Publicado: (2016)

Identification of positron emission tomography (PET) tracer candidates by prediction of the target-bound fraction in the brain
por: Fridén, Markus, et al.
Publicado: (2014)

Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue
por: Aguero, Cinthya, et al.
Publicado: (2019)

Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging
por: Murugan, N. Arul, et al.
Publicado: (2019)

Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases
por: Malarte, Mona-Lisa, et al.
Publicado: (2020)

Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer’s Tauopathy
por: Murugan, N. Arul, et al.
Publicado: (2021)

Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
por: Triana‐Baltzer, Gallen, et al.
Publicado: (2021)

PIKfyve activity is required for lysosomal trafficking of tau aggregates and tau seeding
por: Soares, Alberto Carpinteiro, et al.
Publicado: (2021)

JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis
por: Heinicke, Ulrike, et al.
Publicado: (2015)

Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2022)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
por: Neijssen, Joost, et al.
Publicado: (2021)

A study on the effect of JNJ-10397049 on proliferation and differentiation of neural precursor cells
por: Karami, Neda, et al.
Publicado: (2022)

Discovery and preclinical characterization of [(18)F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies
por: Kroth, Heiko, et al.
Publicado: (2019)

Insight into the Binding of First- and Second-Generation PET Tracers to 4R and 3R/4R Tau Protofibrils
por: Li, Junhao, et al.
Publicado: (2023)

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
por: Doré, Vincent, et al.
Publicado: (2022)

Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
por: Lemoine, Laetitia, et al.
Publicado: (2017)

Dosimetry and efficacy of a tau PET tracer [(18)F]MK-6240 in Japanese healthy elderly and patients with Alzheimer’s disease
por: Ohnishi, Akihito, et al.
Publicado: (2022)

Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid
por: Triana-Baltzer, Gallen, et al.
Publicado: (2020)

Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice
por: Stancu, Ilie-Cosmin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6am50gv7dcmu7091uus04h37p7